Hopstem Biotechnology Inc. (hereinafter referred to as "Hopstem"), a company dedicated to the development of induced ...

Currently in phase 2 trials, BB-031 is the first new mechanistic approach to ischemic stroke treatment in nearly 30 years.

Lowering of infarct growth – brain tissue loss – by 50% in patients treated in less than 12 hours following last known well Lowering of infarct growth correlated with clinically meaningful ...

TACOMA, Wash., May 21, 2025 /PRNewswire/ -- Revalesio, a clinical-stage pharmaceutical company developing treatments for acute and chronic neurological disorders, today announced data from a post hoc ...

Prolong Pharmaceuticals to Present Phase 1/2 Data from HEMERA-1 for PP-007 in Acute Ischemic Stroke (AIS) at the 2025 World Stroke Conference (WSC) Prolong Pharmaceuticals, LLC (the Company), a ...

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal ...

According to the CDC, each year more than 795,000 people in the US have a stroke, of which 610,000 first-time strokes. About 140,000 Americans die from stroke each year — about 1 out of every 20 ...

SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (BCDA) [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...

Trial met primary endpoints of similar rates of serious adverse events (SAEs) and fewer deaths observed with RNS60 versus placebo Statistically significant reduction in infarct growth (brain tissue ...

Hopstem Biotechnology Inc. (hereinafter referred to as "Hopstem"), a company dedicated to the development of induced ...